» Articles » PMID: 26113417

Deregulation of Fas Ligand Expression As a Novel Cause of Autoimmune Lymphoproliferative Syndrome-like Disease

Abstract

Autoimmune lymphoproliferative syndrome is frequently caused by mutations in genes involved in the Fas death receptor pathway, but for 20-30% of patients the genetic defect is unknown. We observed that treatment of healthy T cells with interleukin-12 induces upregulation of Fas ligand and Fas ligand-dependent apoptosis. Consistently, interleukin-12 could not induce apoptosis in Fas ligand-deficient T cells from patients with autoimmune lymphoproliferative syndrome. We hypothesized that defects in the interleukin-12 signaling pathway may cause a similar phenotype as that caused by mutations of the Fas ligand gene. To test this, we analyzed 20 patients with autoimmune lymphoproliferative syndrome of unknown cause by whole-exome sequencing. We identified a homozygous nonsense mutation (c.698G>A, p.R212*) in the interleukin-12/interleukin-23 receptor-component IL12RB1 in one of these patients. The mutation led to IL12RB1 protein truncation and loss of cell surface expression. Interleukin-12 and -23 signaling was completely abrogated as demonstrated by deficient STAT4 phosphorylation and interferon γ production. Interleukin-12-mediated expression of membrane-bound and soluble Fas ligand was lacking and basal expression was much lower than in healthy controls. The patient presented with the classical symptoms of autoimmune lymphoproliferative syndrome: chronic non-malignant, non-infectious lymphadenopathy, splenomegaly, hepatomegaly, elevated numbers of double-negative T cells, autoimmune cytopenias, and increased levels of vitamin B12 and interleukin-10. Sanger sequencing and whole-exome sequencing excluded the presence of germline or somatic mutations in genes known to be associated with the autoimmune lymphoproliferative syndrome. Our data suggest that deficient regulation of Fas ligand expression by regulators such as the interleukin-12 signaling pathway may be an alternative cause of autoimmune lymphoproliferative syndrome-like disease.

Citing Articles

Cytolytic CD4 and CD8 Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease.

Bolivar-Wagers S, Larson J, Jin S, Blazar B Front Immunol. 2022; 13:864748.

PMID: 35493508 PMC: 9040077. DOI: 10.3389/fimmu.2022.864748.


Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.

Lopez-Nevado M, Gonzalez-Granado L, Ruiz-Garcia R, Pleguezuelo D, Cabrera-Marante O, Salmon N Front Immunol. 2021; 12:671755.

PMID: 34447369 PMC: 8382720. DOI: 10.3389/fimmu.2021.671755.


Flow Cytometry Contributions for the Diagnosis and Immunopathological Characterization of Primary Immunodeficiency Diseases With Immune Dysregulation.

Cabral-Marques O, Schimke L, de Oliveira Jr E, El Khawanky N, Ramos R, Al-Ramadi B Front Immunol. 2019; 10:2742.

PMID: 31849949 PMC: 6889851. DOI: 10.3389/fimmu.2019.02742.


Mendelian susceptibility to mycobacterial disease: 2014-2018 update.

Rosain J, Kong X, Martinez-Barricarte R, Oleaga-Quintas C, Ramirez-Alejo N, Markle J Immunol Cell Biol. 2018; 97(4):360-367.

PMID: 30264912 PMC: 6438774. DOI: 10.1111/imcb.12210.


Impaired IL-12- and IL-23-Mediated Immunity Due to IL-12Rβ1 Deficiency in Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease.

Nekooie-Marnany N, Deswarte C, Ostadi V, Bagherpour B, Taleby E, Ganjalikhani-Hakemi M J Clin Immunol. 2018; 38(7):787-793.

PMID: 30255293 PMC: 6469360. DOI: 10.1007/s10875-018-0548-1.


References
1.
Kilinc M, Rowswell-Turner R, Gu T, Virtuoso L, Egilmez N . Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol. 2009; 183(12):7656-60. DOI: 10.4049/jimmunol.0902625. View

2.
Hong Y, Lee C . Autoimmune lymphoproliferative syndrome-like syndrome presented as lupus-like syndrome with mycobacterial joint infection evolved into the lymphoma. Rheumatol Int. 2008; 29(5):569-73. DOI: 10.1007/s00296-008-0707-4. View

3.
McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F . Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010; 26(16):2069-70. PMC: 2916720. DOI: 10.1093/bioinformatics/btq330. View

4.
Oliveira J, Bleesing J, Dianzani U, Fleisher T, Jaffe E, Lenardo M . Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010; 116(14):e35-40. PMC: 2953894. DOI: 10.1182/blood-2010-04-280347. View

5.
Magerus-Chatinet A, Neven B, Stolzenberg M, Daussy C, Arkwright P, Lanzarotti N . Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest. 2010; 121(1):106-12. PMC: 3007148. DOI: 10.1172/JCI43752. View